Analysis of the condition of the kallikrein-kinin system in the comorbid course of chronic pancreatitis and type 2 diabetes




chronic pancreatitis, type 2 diabetes mellitus, kallikrein-kinin system, the proteolytic activity of plasma, α2-macroglobulin


Background. According to evidence, within approximately 8 years, 50 % of patients with chronic pancreatitis (CP) develop endocrine and exocrine insufficiency, which manifests itself as steatorrhea, weight loss, diabetes mellitus (DM), and nutritional disorders. Diabetes mellitus aggravates these phenomena, which deepens the disorder of metabolic processes in CP, inclu­ding protein metabolism. Protein structures include components of the kallikrein-kinin system (KKS), which plays a role in the regulation of vascular tone, diuresis, inflammation, coagulation, and pain reception. Due to repeated exacerbations of pancreatitis, there is fibrosis of the pancreas, which increases the risk of insulin resistance and the formation of type 2 diabetes. Thus, di­sorders of the kallikrein-kinin system and the progression of CP are interrelated, which makes it important to study the state of KKS in CP, especially in combination with type 2 diabetes mellitus. The purpose is to investigate the state of the kallikrein-kinin system in chronic pancreatitis in outpatients, depending on the presence of concomitant type 2 diabetes. Material and methods. 137 outpatients with CP with concomitant diabetes mellitus and without dia­betes were studied: the main group — 112 patients with CP without exacerbation in combination with diabetes mellitus in a state of complete or subcompensation, and the comparison group — 25 patients with isolated CP. Evaluation of general and specific proteolysis (α1-proteinase inhibitor, α2-macroglobulin, kallikrein, kininase II activity, prekallikrein, plasma proteolytic activity) was performed by the method analysis using standard kits from BIOSERV ELISA. Results. There was a 20.8 % increase in the level of the total proteolytic activity of plasma in the group of patients with comorbidity of CP and diabetes mellitus compared with the group with isolated CP, 51.9 % increase in specific proteolysis (or kininogenesis) — the level of kallikrein (proteolysis enzyme), p < 0.05. At the same time, a decrease in prekallikrein (inactive precursor of kallikrein) was found in the group of patients with comorbidity by 19.4 % compared to that in isolated CP (p < 0.05). The presence of dissociation of protective parameters of kallikrein-kinin system is proved; increase by 9.4 % of α1-proteinase inhibitor content at comorbidity of CP and DM2 in relation to that in isolated CP; decrease in the content of α2-macroglobulin in CP relative to the control group (p < 0.05), which showed a decrease in the body’s compensatory capacity in CP, at the same time found an increase in α2-macroglobulin in the comorbidity of CP with DM2 by 49.5 % relative to isolated CP; reduction of kininase-II activity in CP and diabetes mellitus by 14.5 % relative to that in CP. Conclusions. Activation of KKS with multidirectional changes in KKS parameters and general and specific proteolysis in CP was noted. In CP and in the comorbid course with diabetes mellitus, further activation of proteolysis took place with the simultaneous inclusion of protective mechanisms for resolving inflammation and detoxification. Excessive production of kinins in concomitant DM2 has been proven, which weakened the body’s protective response.


Download data is not yet available.


Redkva OV, Babinets LS, Halabitska IM. Evaluation of parameters of actual typical pathogenetic syndromes in comorbidity of type 2 diabetes mellitus and chronic pancreatitis. Wiad Lek. 2021;74(10 cz 2):2557 -2559.

Babinets LS, Halabitska IM, Borovyk IO, Redkva OV, Sasyk HM. The influence of exocrine pancreatic insufficiency in the formation of osteopenia in patients with primary osteoarthritis. Wiad Lek. 2020;73(10):2238-2240.

Babinets LS, Shevchenko NA, Sasyk HM, Zemlyak OS. Research of lipid exchange diffusion of medium-age patients with chronic pancreatitis with diabetes mellitus. Journal of Education, Health and Sport formerly journal of Health Sciences. 2017;7(11):309-318. doi:10.5281/zenodo.1136094.

Bellin MD, Whitcomb DC, Abberbock J, et al. Patient and disease characteristics associated with the presence of diabetes mellitus in adults with chronic pancreatitis in the United States. Am J Gastroenterol. 2017 Sep;112(9):1457-1465. doi:10.1038/ajg.2017.181.

Domínguez Muñoz JE, Lucendo Villarín AJ, Carballo Álvarez LF, Tenías JM, Iglesias García J. Spanish multicenter study to estimate the incidence of chronic pancreatitis. Rev Esp Enferm Dig. 2016 Jul;108(7):411-416. doi:10.17235/reed.2016.4056/2015.

Lévy P, Domínguez-Muñoz E, Imrie C, Löhr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. United European Gastroenterol J. 2014 Oct;2(5):345-354. doi:10.1177/2050640614548208.

Lew D, Afghani E, Pandol S. Chronic Pancreatitis: Current Status and Challenges for Prevention and Treatment. Dig Dis Sci. 2017 Jul;62(7):1702-1712. doi:10.1007/s10620-017-4602-2.

Melitas C, Meiselman M. Metabolic pancreatitis: pancreatic steatosis, hypertriglyceridemia, and associated chronic pancreatitis in 3 patients with metabolic syndrome. Case Rep Gastroenterol. 2018 Jun 25;12(2):331-336. doi:10.1159/000490042.

Schrader H, Menge BA, Zeidler C, et al. Determinants of glucose control in patients with chronic pancreatitis. Diabetologia. 2010 Jun;53(6):1062-1069. doi:10.1007/s00125-010-1705-0.

Whitcomb DC. Primer on precision medicine for complex chronic disorders. Clin Transl Gastroenterol. 2019 Jul;10(7):e00067. doi:10.14309/ctg.0000000000000067.

Yang D, Forsmark CE. Chronic pancreatitis. Curr Opin Gastroenterol. 2017 Sep;33(5):396-403. doi:10.1097/MOG.0000000000000377.

Yu JH, Kim H. Oxidative stress and inflammatory signaling in cerulein pancreatitis. World J Gastroenterol. 2014 Dec 14;20(46):17324-17329. doi:10.3748/wjg.v20.i46.17324.

Samantha Sykioti V, Karampetsou M, Chalatsa I, et al. Deficiency of the serine peptidase Kallikrein 6 does not affect the levels and the pathological accumulation of a-synuclein in mouse brain. J Neurochem. 2021 Jun;157(6):2024-2038. doi:10.1111/jnc.15199.

Yoon H, Triplet EM, Simon WL, et al. Blocking Kallikrein 6 promotes developmental myelination. Glia. 2022 Mar;70(3):430-450. doi:10.1002/glia.24100.

Yoon H, Scarisbrick IA. Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis. Biol Chem. 2016 Dec 1;397(12):1277-1286. doi:10.1515/hsz-2016-0239.

Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002 Jul 5;277(27):24562-70. doi:10.1074/jbc.M202392200.

Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi:10.1038/nrd4534.

Srinivasan S, Kryza T, Batra J, Clements J. Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nat Rev Cancer. 2022 Apr;22(4):223-238. doi:10.1038/s41568-021-00436-z.



How to Cite

Babinets, L., & Halabitska, I. (2022). Analysis of the condition of the kallikrein-kinin system in the comorbid course of chronic pancreatitis and type 2 diabetes. GASTROENTEROLOGY, 56(2), 69–73.



Original Researches

Most read articles by the same author(s)

1 2 > >>